Nouvelle déclaration d'incident
No de la demande: 2009-2141
Numéro de référence du titulaire d'homologation: SC477945
Nom du titulaire (nom légal complet, aucune abbréviation): Dow AgroSciences Canada Inc.
Adresse: 450-1st Street SW, Suite 2100
Ville: Calgary
État: AB
Pays: Canada
Code postal /Zip: T2P 5H1
Incident chez l'humain
Pays: UNITED STATES
État: FLORIDA
Inconnu
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Lorsban (non-specific)
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Dormant oil
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Rubigon
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Polyram
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Imidan
Liquide
Oui
Inconnu
Non
Personne affectée
Sexe: Homme
Âge: >64 yrs / > 64 ans
Système
>6 mos / > 6 mois
Oui
Non
Professionnel
Application
Aucun
Peau
Respiratoire
>1 mo <= 6 mos / > 1 mois < = 6 mois
Unknown / Inconnu
5/27/2009 Caller reports working for a company periodically from 1996 to 1998 during which time caller used a handmade spraying device containing a mixture of the products at an unknown dilution rate. Caller would mix the products using a coffee cup, and did not wear gloves or a respirator during application. Caller had product splash onto both hands hands and would breath product during application, and never would decontaminate after application. Some time after this, caller could not be specific, caller developed flu-like symptoms. Six months later caller developed tingling in both hands, burning in the lungs, unsteady gate, nightmares, irregular heart beat, and spots in the visual field. Caller has seen multiple doctors, and was diagnosed with chronic organophosphate neurological dysfunction as well as lung function impairment. Caller states that acetylcholinesterase was tested in 1999, and caller believes the results were high. Caller is currently taking psychiatric medication and performing physical therapy for treatment for his continued disability.
Majeure
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews. When considering the body of regulatory data as well as the weight of scientific peer reviewed data, a causal relationship between the individual ingredients used in the various products implicated in this case and the insidious/delayed medical complications reported by this patient lacks any biological plausibility. Furthermore, a report of elevated cholinesterase activity in 1999 would suggest that significant exposure to a cholinesterase inhibitor like Lorsban has been ruled out, at least as far as acute exposure is concerned.